Differential Diagnosis of Hyperandrogenism in Women with Polycystic Ovary Syndrome

Abstract

According to the Androgen Excess and Polycystic Ovary Syndrome Society (AE&PCOS), the main feature of PCOS is clinical hyperandrogenism or laboratory hyperandrogenaemia. Therefore, in diagnosing PCOS one must always exclude other causes of androgen excess. In a woman with hyperandrogenism, the diagnosis of PCOS can usually be made according to the patient’s history and careful clinical examination. Signs of mild hyperandrogenaemia usually start after the menarche and cycles continue to be anovulatory in adult life. Non-classical congenital adrenal hyperplasia (NCCAH) can be another cause of hyperandrogenism with oligomenorrhea. This can be diagnosed in a patient with elevated basal or ACTH stimulated serum 17OH-progesterone (17-OHP) levels or in a case of a significant decrease in serum testosterone (TST) and dehydroepiandrosterone sulphate (DHEA-S) in a two day dexamethasone suppression test. Cushing’s disease (ACTH producing pituitary adenoma) is a rare cause of hyperandrogenaemia in women with recent onset of hyperandrogenism. However, it must always be taken into the consideration in a patient with accompanying signs of hypercortisolism. It can usually be excluded by performing an overnight dexamethasone suppression test or the measurement of 24 h urinary free cortisol levels. Severe signs of hyperandrogenism which lead to virilization should always lead to the exclusion of androgen secreting tumors of ovarian or adrenal origin. These are very rare but should be always taken into the account in a patient with recent onset of severe signs of androgen excess and very high serum androgen levels. Mild signs of hyperandrogenaemia in a woman with recent oligomenorrhea should always lead to the exclusion of hyperprolactinaemia.

Key words

PCOS - hyperandrogenism - hirsutism - oligomenorrhea - congenital adrenal hyperplasia - differential diagnosis

• References

• 1 Al-Ahmadie HA, Stanek J, Liu J et al. Ovarian ‘tumor’ of the adrenogenital syndrome: the first reported case. Am J Surg Pathol 2001; 25: 1443-1450
• 2 Azziz R, Carmina E, Dewailly D et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245
• 3 Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21: 347-362
• 4 Azziz R, Hincapie LA, Knochenhauer ES et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999; 72: 915-925
• 5 Azziz R, Sanchez LA, Knochenhauer ES et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89: 453-462
• 6 Carmina E, Koyama T, Chang L et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. Am J Obstet Gynecol 1992; 167: 1807-1812
• 7 Chang WY, Knochenhauer ES, Bartolucci AA et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005; 83: 1717-1723
• 8 Child DF, Bu lock DE, Anderson DC. Adrenal steroidogenesis in hirsute women. Clin Endocrinol (Oxf) 1980; 12: 595-601
• 9 Cohen-Becker IR, Selmanoff M, Wise PM. Hyperprolactinemia alters the frequency and amplitude of pulsatile luteinizing hormone secretion in the ovariectomized rat. Neuroendocrinology 1986; 42: 328-333
• 10 Corenblum B, Taylor PJ. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity. Fertil Steril 1982; 38: 549-552
• 11 Dumic M, Brkljacic L, Mardesic D et al. ‘Cryptic’ form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in the Yugoslav population. Acta Endocrinol (Copenh) 1985; 109: 386-392
• 12 Dumic M, Brkljacic L, Speiser PW et al. An update on the frequency of nonclassic deficiency of adrenal 21-hydroxylase in the Yugoslav population. Acta Endocrinol (Copenh) 1990; 122: 703-710
• 13 Faredin I, Toth I. Metabolism and concentration of androgenic steroids in the abdominal skin of women with idiopathic hirsutism. Acta Med Hung 1984; 41: 19-34
• 14 Friedman CI, Schmidt GE, Kim MH et al. Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol 1985; 153: 44-49
• 15 Gibson M, Lackritz R, Schiff I et al. Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women. Fertil Steril 1980; 33: 43-48
• 16 Judd HL, Scully RE, Herbst AL et al. Familial hyperthecosis: comparison of endocrinologic and histologic findings with polycystic ovarian disease. Am J Obstet Gynecol 1973; 117: 976-982
• 17 Kohn B, Levine LS, Pollack MS et al. Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 1982; 55: 817-827
• 18 Kumar A, Woods KS, Bartolucci AA et al. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005; 62: 644-649
• 19 Legro RS, Shahbahrami B, Lobo RA et al. Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994; 83: 701-706
• 20 Levine LS, Dupont B, Lorenzen F et al. Cryptic 21-hydroxylase deficiency in families of patients with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 1980; 51: 1316-1324
• 21 Lobo RA, Goebelsmann U. Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. Am J Obstet Gynecol 1980; 138: 720-726
• 22 London DR. The consequences of hyperandrogenism in young women. J R Soc Med 1987; 80: 741-745
• 23 Milenkovic L, D’Angelo G, Kelly PA et al. Inhibition of gonadotropin hormone-releasing hormone release by prolactin from GT1 neuronal cell lines through prolactin receptors. Proc Natl Acad Sci USA 1994; 91: 1244-1247
• 24 Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 1986; 154: 384-389
• 25 New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4205-4214
• 26 New MI, Wilson RC. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci USA 1999; 96: 12790-12797
• 27 Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 28 Richards GE, Grumbach MM, Kaplan SL et al. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 47: 1208-1215
• 29 Rumsby G, Fielder AH, Hague WM. Honour JW. Heterogeneity in the gene locus for steroid 21-hydroxylase deficiency. J Med Genet 1988; 25: 596-599
• 30 Russo G, Paesano P, Taccagni G et al. Ovarian adrenal-like tissue in congenital adrenal hyperplasia. N Engl J Med 1998; 339: 853-854
• 31 Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998; 3: 9-15
• 32 Serafini P, Lobo RA. Increased 5 alpha-reductase activity in idiopathic hirsutism. Fertil Steril 1985; 43: 74-78
• 33 Sherman SL, Aston CE, Morton NE et al. A segregation and linkage study of classical and nonclassical 21-hydroxylase deficiency. Am J Hum Genet 1988; 42: 830-838
• 34 Speiser PW, Dupont B, Rubinstein P et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985; 37: 650-667
• 35 Stikkelbroeck NM, Hermus AR, Braat DD et al. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003; 58: 275-284
• 36 Tusie-Luna MT, Traktman P, White PC. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 1990; 265: 20916-20922
• 37 Wentz AC. Treatment of luteal phase defects. J Reprod Med 1977; 18: 159-162
• 38 Yanovski JA, Cutler Jr GB, Chrousos GP et al. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. Jama 1993; 269: 2232-2238
• 39 Zerah M, Ueshiba H, Wood E et al. Prevalence of nonclassical steroid 21-hydroxylase deficiency based on a morning salivary 17-hydroxyprogesterone screening test: a small sample study. J Clin Endocrinol Metab 1990; 70: 1662-1667